Melittin Dosing & Reconstitution Guide

Melittin is primarily recognized as a component of bee venom, and thus traditional dosing routes and frequencies are not applicable. The peptide has demonstrated notable cytotoxic effects, limiting its systemic application. In vitro studies have reported effective concentrations ranging from 1 to 50 mcg/mL, depending on the specific experimental context and desired outcomes. Researchers should exercise caution, as the cytotoxic nature of Melittin necessitates careful consideration of its concentration and exposure duration during experiments. The absence of a standardized dosing regimen underscores the importance of tailored approaches based on empirical data derived from relevant studies.

Melittin exhibits significant hemolytic activity at micromolar concentrations, which poses a considerable challenge for systemic use. This characteristic can lead to intense pain, local inflammation, and edema at the injection site, making its application in vivo particularly problematic. Furthermore, individuals with known allergies to bee venom or a history of anaphylaxis related to Hymenoptera stings face a heightened risk of severe allergic reactions, potentially leading to life-threatening situations. Additional contraindications include severe cardiac, hepatic, or renal disease, as well as pregnancy and breastfeeding, where the risks associated with Melittin exposure may outweigh potential benefits. Researchers must remain vigilant about these safety considerations when planning studies involving this peptide.